238 related articles for article (PubMed ID: 28642281)
1. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.
Kato S; Krishnamurthy N; Banks KC; De P; Williams K; Williams C; Leyland-Jones B; Lippman SM; Lanman RB; Kurzrock R
Cancer Res; 2017 Aug; 77(16):4238-4246. PubMed ID: 28642281
[TBL] [Abstract][Full Text] [Related]
2. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.
Schwaederle M; Chattopadhyay R; Kato S; Fanta PT; Banks KC; Choi IS; Piccioni DE; Ikeda S; Talasaz A; Lanman RB; Bazhenova L; Kurzrock R
Cancer Res; 2017 Oct; 77(19):5419-5427. PubMed ID: 28807936
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
4. Genetic characterisation of molecular targets in carcinoma of unknown primary.
Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
[TBL] [Abstract][Full Text] [Related]
5. Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary.
Kolbinger FR; Bernard V; Lee JJ; Stephens BM; Branchi V; Raghav KPS; Maitra A; Guerrero PA; Semaan A
J Gastrointest Cancer; 2023 Dec; 54(4):1276-1285. PubMed ID: 36862364
[TBL] [Abstract][Full Text] [Related]
6. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.
Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Patel SP; Harismendy O; Ikeda M; Parker BA; Kurzrock R
Clin Cancer Res; 2016 Nov; 22(22):5497-5505. PubMed ID: 27185373
[TBL] [Abstract][Full Text] [Related]
7. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
[TBL] [Abstract][Full Text] [Related]
8. Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).
Es HA; Mahdizadeh H; Asl AAH; Totonchi M
Sci Rep; 2021 Jul; 11(1):15112. PubMed ID: 34302033
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary.
Kato S; Weipert C; Gumas S; Okamura R; Lee S; Sicklick JK; Saam J; Kurzrock R
JCO Precis Oncol; 2021; 5():. PubMed ID: 34778692
[TBL] [Abstract][Full Text] [Related]
10. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.
Varghese AM; Arora A; Capanu M; Camacho N; Won HH; Zehir A; Gao J; Chakravarty D; Schultz N; Klimstra DS; Ladanyi M; Hyman DM; Solit DB; Berger MF; Saltz LB
Ann Oncol; 2017 Dec; 28(12):3015-3021. PubMed ID: 29045506
[TBL] [Abstract][Full Text] [Related]
12. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
Hahn AW; Gill DM; Maughan B; Agarwal A; Arjyal L; Gupta S; Streeter J; Bailey E; Pal SK; Agarwal N
Oncotarget; 2017 May; 8(20):33614-33620. PubMed ID: 28431395
[TBL] [Abstract][Full Text] [Related]
13. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.
Ikeda S; Elkin SK; Tomson BN; Carter JL; Kurzrock R
Cancer Biol Ther; 2019; 20(2):219-226. PubMed ID: 30339521
[TBL] [Abstract][Full Text] [Related]
15. The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA.
Riviere P; Fanta PT; Ikeda S; Baumgartner J; Heestand GM; Kurzrock R
Mol Cancer Ther; 2018 Jan; 17(1):297-305. PubMed ID: 29133621
[TBL] [Abstract][Full Text] [Related]
16. Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer.
Beránek M; Sirák I; Vošmik M; Petera J; Drastíková M; Palička V
Acta Medica (Hradec Kralove); 2016; 59(2):54-8. PubMed ID: 27526306
[TBL] [Abstract][Full Text] [Related]
17. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
[TBL] [Abstract][Full Text] [Related]
18. A Carcinoma of Unknown Primary (CUP) Patient Treated Successfully With Immunotherapy Upon Recognition of Deficient Mismatch Repair Signature on Liquid Biopsy: A Case Report.
Cox RE; Chakrabarti S
Cureus; 2022 Jul; 14(7):e27184. PubMed ID: 36017278
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
